JPRN-C000000330
Completed
Phase 2
Peripheral blood mononuclear cell therapy in PAD patients with intermittent claudication randamized trial - PB-MNC therapy (PERTINENT) trial
Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine0 sites60 target enrollmentFebruary 15, 2006
ConditionsASO/Buerger disease
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- ASO/Buerger disease
- Sponsor
- Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients with malignant diseases, severe diabetic retinopathy, or severe renal failure.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Peripheral blood mononuclear cell therapy in PAD patientsPeripheral artery disease due to collagen diseaseJPRN-UMIN000000764Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine20
Unknown
Not Applicable
Peripheral blood mononuclear cell implantation for patients with severe ischemic heart diseaseSevere ischemic heart diseaseJPRN-UMIN000001289Department of Cardiovascular Science and Medicine,Graduate School of Medicine,Chiba University30
Completed
Phase 1
Safety and Efficacy Study of Peripheral Blood Mononucleated Cells for Treatment of Liver CirrhosisLiver CirrhosisNCT01503749Seoul National University Hospital9
Completed
Phase 1
PBMC-therapy and treatment of recurrent implantation failure (RIF)IRCT2017081227520N8Stem Cell And Regenerative Medicine Institute,Tabriz University of Medical Sciences100
Active, not recruiting
Not Applicable
Immunotherapy by autologous peripheral blood mononuclear cells and GM-CSF for hepatocellular carcinoma undergoing radiofrequency thermal ablation - HCC thermal ablation and immunotherapy combined treatmentpatients with hepatocellular carcinomaMedDRA version: 9.1Level: LLTClassification code 10059319Term: Hepatic cancer stage IIEUCTR2008-003925-17-ITAZIENDA OSPEDALIERA DI PARMA